In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Altimmune Inc. (NASDAQ:ALT) reported that Ofco Club V has picked up 1,164,190 of common stock as of 2017-05-15.
The acquisition brings the aggregate amount owned by Ofco Club V to a total of 1,164,190 representing less than 7.5% stake in the company.
For those not familiar with the company, Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies, RespirVec and Densigen. Its candidates include NasoVAX, HepTcell, NasoShield and Oncosyn. NasoVAX is an intranasally administered recombinant influenza vaccine. The Company has completed Phase I clinical trials of NasoVAX. HepTcell is being tested as an immunotherapy for patients chronically infected with the hepatitis B virus. NasoShield is an intranasal, single-dose anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. Oncosyn is being developed as a cancer immunotherapeutic product candidate. Oncosyn targets multiple tumor antigens simultaneous to prevent tumor escape.
A glance at Altimmune Inc. (NASDAQ:ALT)’s key stats reveals a current market capitalization of 38.19 Million based on 6.88 Million shares outstanding and a price at last close of $5.55 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-03-19, St picked up 25,000 at a purchase price of $1.65. This brings their total holding to 25,000 as of the date of the filing.
On the sell side, the most recent transaction saw Prescott unload 436,324 shares at a sale price of $3.26. This brings their total holding to 6,626,403.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Altimmune Inc. (NASDAQ:ALT) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.